MEDPMedpace Holdings, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for ~6% a year FCF growth. The price demands less than its three-year revenue growth of 18% a year, expectations look modest.
In its normal range: P/E 36.0 vs a 32.4 median over 40 quarters (+11% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What MEDP's price assumes
Medpace Holdings, Inc. trades at 36.0× earnings against 35.2× for the median Diagnostics & Research name, more expensive than its own group.
Trailing P/E · Diagnostics & Research median 35.2 · 1.02× the median: the market pays up for this one
- Price / sales
- 5.34
Price / sales · as of 2026-Q2
- Free cash flow yield
- 4.8%
Free cash flow yield · Diagnostics & Research median 3.7%
- Growth the price implies
- +6.3%
Growth the price implies · The price pays for +6.3% free cash flow growth a year for a decade; the business has delivered +24% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 34.2
- Healthcare median P/E509 names
- 26.2
- Diagnostics & Research median P/E33 names
- 35.2
- Free cash flow, trailing twelve months
- $707M
- Market capitalisation
- $14.8B
- 3-year revenue growth
- +18%
- 3-year free cash flow growth
- +24%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $483.11 |
| Its own P/E history, median | $551.98 |
| Its own P/E history, upper quartile | $652.21 |
| 52-week range | $393.42 – $630.21 |
| Today | $612.15 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #1 of 21 by RyuScore